INTS SEC Filings - Intensity Therapeutics, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1567264

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Intensity Therapeutics, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

August 28, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
August 12, 2025	EX-3.1	AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF INTENSITY THERAPEUTICS, INC. Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF INTENSITY THERAPEUTICS, INC. This Amendment (this “Amendment”) to the Amended and Restated Bylaws (the “Bylaws”) of Intensity Therapeutics, Inc., a Delaware corporation (the “Company”), is effective as of August 12, 2025 and is made pursuant to Article X of the Bylaws. 1. Section 2.7 of Article II of the Bylaws is hereby amended by deleti
August 12, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Intensity Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
August 7, 2025	EX-99.1	Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update •Over $11 million raised since the beginning of 2Q 2025 •Cash runway extended into the second half of 2026 •In the INVINCIBLE-4 Study, patients receiving INT230-6 prior to the start of standard of care achieved high levels of tumor necrosis in 8 days •INT230-6 achieved 100% complete resp
August 4, 2025	EX-99.1	Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 Exhibit 99.1 Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 •Cash runway extended into the second half of 2026 •Average sales price per share was over 10% higher than the June 2025 public offering price Shelton, Connecticut – August 4, 2025 – Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or “the Company”), a late-stage clinica
August 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Intensity Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
July 18, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commiss
June 27, 2025	S-8	As filed with the Securities and Exchange Commission on June 27, 2025 As filed with the Securities and Exchange Commission on June 27, 2025 Registration No.
June 27, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Intensity Therapeutics, Inc.
June 18, 2025	424B5	INTENSITY THERAPEUTICS, INC. Up to $9,650,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280681 PROSPECTUS SUPPLEMENT No. 3 (To the Sales Agreement Prospectus dated July 11, 2024 and the Base Prospectus, dated July 11, 2024) INTENSITY THERAPEUTICS, INC. Up to $9,650,000 Common Stock We have previously entered into an at the market offering agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) relating
June 13, 2025	EX-99.2	Intensity Therapeutics, Inc. Announces Pricing of Public Offering Exhibit 99.2 Intensity Therapeutics, Inc. Announces Pricing of Public Offering Shelton, Conn., June 11, 2025 – Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or the “Company”), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Intensity Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commiss
June 13, 2025	EX-99.1	Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Shelton, Conn., June 11, 2025 – Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or the “Company”), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune syste
June 13, 2025	EX-1.1	Underwriting Agreement, dated June 11, 2025, by and between the Company and ThinkEquity LLC. Exhibit 1.1 UNDERWRITING AGREEMENT between INTENSITY THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters INTENSITY THERAPEUTICS, INC. UNDERWRITING AGREEMENT New York, New York June 11, 2025 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: The
June 12, 2025	424B5	The date of this prospectus supplement is June 11, 2025. TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-280681 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 11, 2024) 6,675,000 Shares of Common Stock Intensity Therapeutics, Inc. We are offering shares of our common stock par value $0.0001 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price of $0.30 per share. Our common
June 11, 2025	424B5	The date of this prospectus supplement is June , 2025. TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-280681 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su
June 11, 2025	FWP	A New Weapon in the War on Cancer P R E S E N TAT I O N NASDAQ: INTS Q2 2025 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-280681 June 11, 2025 2 2 This presentation contains forward‐looking statements within the mean intensity-fwp A New Weapon in the War on Cancer P R E S E N TAT I O N NASDAQ: INTS Q2 2025 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No.
June 11, 2025	424B5	INTENSITY THERAPEUTICS, INC. Up to $15,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280681 PROSPECTUS SUPPLEMENT No. 2 (To the Sales Agreement Prospectus dated July 11, 2024 and the Base Prospectus, dated July 11, 2024) INTENSITY THERAPEUTICS, INC. Up to $15,000 Common Stock We have previously entered into an at the market offering agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) relating to
June 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 Intensity Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commissi
June 2, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
June 2, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
May 20, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commissi
May 13, 2025	EX-99.1	Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update •Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treated •European Medicines Agency Authorization to initiate INVINCIBLE-4-Study in France Shelton, Conn., May 13, 2025 – Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
May 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Intensity Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commissi
April 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Intensity Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
April 25, 2025	EX-4.2	Form of Series B-2 Common Warrant. Exhibit 4.2 SERIES B-2 COMMON STOCK PURCHASE WARRANT INTENSITY THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: April 28, 2025 Issue Date: April 28, 2025 THIS SERIES B-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for
April 25, 2025	EX-4.1	Form of Series B-1 Common Warrant. Exhibit 4.1 SERIES B-1 COMMON STOCK PURCHASE WARRANT INTENSITY THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: April 28, 2025 Issue Date: April 28, 2025 THIS SERIES B-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for
April 25, 2025	EX-99.1	Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering Exhibit 99.1 Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering SHELTON, Conn., Apr. 25, 2025 /PRNewswire/ - Intensity Therapeutics, Inc. (NASDAQ: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune sys
April 25, 2025	424B4	3,133,333 Shares of Common Stock 3,133,333 Series B-1 Common Warrants to Purchase Up to 3,133,333 Shares of Common Stock 3,133,333 Series B-2 Common Warrants to Purchase Up to 3,133,333 Shares of Common Stock 6,266,666 Shares of Common Stock Underlyi PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-286683 3,133,333 Shares of Common Stock 3,133,333 Series B-1 Common Warrants to Purchase Up to 3,133,333 Shares of Common Stock 3,133,333 Series B-2 Common Warrants to Purchase Up to 3,133,333 Shares of Common Stock 6,266,666 Shares of Common Stock Underlying the Series B-1 Common Warrants and Series B-2 Common Warrants We are offeri
April 25, 2025	EX-10.1	Form of Securities Purchase Agreement, dated as of April 24, 2025, by and between Intensity Therapeutics, Inc. and the purchasers party thereto (incorporated by reference to our Form 8-K filed on April 25, 2025). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Intensity Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi
April 24, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Intensity Therapeutics, Inc.
April 24, 2025	S-1/A	As filed with the Securities and Exchange Commission on April 24, 2025. As filed with the Securities and Exchange Commission on April 24, 2025. Registration No. 333-286683 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTENSITY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2836 46-1488089 (State or other jurisdiction of inc
April 24, 2025	EX-10.16	Form of Securities Purchase Agreement Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2025, between Intensity Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition
April 23, 2025	EX-99.1	A New Weapon in the War on Cancer P R E S E N TAT I O N NASDAQ: INTS Q2 2025 Exhibit 99.1 4 4 This presentation contains forward‐looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial ri A New Weapon in the War on Cancer P R E S E N TAT I O N NASDAQ: INTS Q2 2025 Exhibit 99.
April 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Intensity Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
April 23, 2025	FWP	A New Weapon in the War on Cancer P R E S E N TAT I O N April 2025 Issuer free writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-286683 April 22, 2025 3 3 This presentation highlights basic information about Intensity Therapeutics, I intensityfwp A New Weapon in the War on Cancer P R E S E N TAT I O N April 2025 Issuer free writing Prospectus Filed Pursuant to Rule 433 Registration No.
April 22, 2025	EX-1.1	Form of Placement Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [•], 2025 Intensity Therapeutics, Inc. 1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779 Attn: Chief Executive Officer Dear Mr. Bender: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Lead Placement Agent”), Brookline Capital Markets, a division of Arcadia Securities, LLC (the “Co-Placement Agent” and t
April 22, 2025	S-1	As filed with the Securities and Exchange Commission on April 22, 2025. As filed with the Securities and Exchange Commission on April 22, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTENSITY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2836 46-1488089 (State or other jurisdiction of incorporation or organizatio
April 22, 2025	EX-4.6	Form of Pre-Funded Warrant Exhibit 4.6 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT INTENSITY THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: [•], 2025 Issue Date: [•], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaft
April 22, 2025	EX-10.16	orm of Securities Purchase Agreement Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2025, between Intensity Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition
April 22, 2025	EX-4.5	Form of Series B-2 Common Warrant Exhibit 4.5 FORM OF SERIES B-2 COMMON STOCK PURCHASE WARRANT INTENSITY THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: [●], 2025 Issue Date: [●], 2025 THIS SERIES B-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth
April 22, 2025	CORRESP	INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 April 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 Filed April 22, 2025 File No. 333-286683 (the “Registration Statement”) Acceleration Reques
April 22, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Intensity Therapeutics, Inc.
April 22, 2025	EX-4.4	Common Warrant Exhibit 4.4 FORM OF SERIES B-1 COMMON STOCK PURCHASE WARRANT INTENSITY THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: [●], 2025 Issue Date: [●], 2025 THIS SERIES B-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth
March 28, 2025	DRS	Confidential Treatment Requested by Intensity Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 Confidential Treatment Requested by Intensity Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on March 28, 2025. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIE
March 13, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTI Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41109 INTENSIT
March 13, 2025	EX-99.1	Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update Exhibit 99.1 Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update •32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screened •Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screened •Final sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was present
March 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
March 13, 2025	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF SECURITIES The following summary of the material terms of the capital stock of Intensity Therapeutics, Inc. is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Sixth Amended and Restated Certificate of Incorporation, as amended ("amended and restated certificate of incorporation”) and our Second
March 13, 2025	EX-19.1	Insider Trading Policy. Exhibit 19.1 INTENSITY THERAPEUTICS, INC. INSIDER TRADING POLICY Policy Principles 1.Personnel of Intensity Therapeutics, Inc. (“Intensity”) are responsible for understanding the obligations that come with having access to material nonpublic information and wanting to transact in Intensity securities. 2.Intensity personnel who are aware of material nonpublic information relating to Intensity may n
January 7, 2025	CORRESP	INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 January 7, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Sasha Parikh Kevin Vaughn Re: Intensity Therapeutics, Inc. Form 10-K for the year ended December 31, 2023 Filed March 14, 2024 File No. 001-41109 De
December 20, 2024	424B3	Intensity Therapeutics, Inc. 1,237,113 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-283797 PROSPECTUS Intensity Therapeutics, Inc. 1,237,113 Shares of Common Stock The selling stockholder of Intensity Therapeutics, Inc. (“Intensity,” “we,” “us” or the “Company”) listed beginning on page 11 of this prospectus may offer and resell under this prospectus up to 1,237,113 shares of our common stock, par value $0.0001 per share (the
December 17, 2024	CORRESP	INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 December 17, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 Filed December 13, 2024 File No. 333-283797 (the “Registration Statement”) Acceleration Re
December 13, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Intensity Therapeutics, Inc.
December 13, 2024	S-1	As filed with the Securities and Exchange Commission on December 13, 2024 As filed with the Securities and Exchange Commission on December 13, 2024 Registration No.
November 22, 2024	EX-99.1	Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement SHELTON, Conn. – November 21, 2024 – Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the “Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies des
November 22, 2024	424B5	INTENSITY THERAPEUTICS, INC. 1,237,113 Shares Common Stock ` Filed Pursuant to Rule 424(b)(5) Registration No. 333-280681 Prospectus Supplement (To prospectus dated July 11, 2024) INTENSITY THERAPEUTICS, INC. 1,237,113 Shares Common Stock We are offering 1,237,113 shares of our common stock directly to an institutional investor pursuant to this prospectus supplement and the accompanying prospectus. Each share of common stock will be sold in this offering
November 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 Intensity Thera UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Com
November 22, 2024	EX-10.1	Form of Securities Purchase Agreement, dated as of November 21, 2024, by and between Intensity Therapeutics, Inc. and the purchasers party thereto Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November [], 2024, between Intensity Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co
November 22, 2024	EX-4.1	Form of November 2024 Common Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
November 22, 2024	EX-1.1	Form of Placement Agent Agreement, dated as of November 21, 2024, by and between Intensity Therapeutics, Inc. and A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Solutions, LLC Exhibit 1.1 PLACEMENT AGENCY AGREEMENT November [], 2024 Intensity Therapeutics, Inc. 1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779 Attn: Chief Executive Officer Dear Mr. Bender: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Lead Placement Agent”), Brookline Capital Markets, a division of Arcadia Securities, LLC (the “Co-Placement Agen
November 20, 2024	424B5	INTENSITY THERAPEUTICS, INC. Up to $7,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280681 PROSPECTUS SUPPLEMENT No. 1 (To the Sales Agreement Prospectus dated July 11, 2024 and the Base Prospectus, dated July 11, 2024) INTENSITY THERAPEUTICS, INC. Up to $7,000,000 Common Stock We have entered into an at the market offering agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) relating to shares o
November 13, 2024	EX-99.1	Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer Exhibit 99.1 Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer Shelton, Conn., November 13, 2024 – Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and developmen
November 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Com
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
October 23, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Comm
August 8, 2024	EX-10.1	Collaboration Agreement, dated May 6, 2024, between the Registrant and The Swiss Group for Cancer Research SAKK Exhibit 10.1 Collaboration Agreement between Intensity Therapeutics 1 Enterprise Drive, Suite 430, Shelton CT 06484; USA ("Intensity"). (hereinafter “Partner”) and The Swiss Group for Clinical Cancer Research SAKK Effingerstrasse 33, CH-Bern, 3008, Switzerland (hereinafter “SAKK”) Partner and the SAKK hereinafter also referred to as “Party” or jointly “the Parties” regarding The trial SAKK 66/22 “
August 8, 2024	EX-99.1	Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update •First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma •Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK (“SAKK”) to conduct a Phase 2 randomized, study in early-stage breast cancer in Europe •Cash and investments of $6.3
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001
July 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commiss
July 9, 2024	CORRESP	INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 July 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Intensity Therapeutics, Inc. Registration Statement on Form S-3 Filed July 3, 2024 File No. 333-280681 (the “Registration Statement”) Acceleration Request La
July 9, 2024	CORRESP	INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 INTENSITY THERAPEUTICS, INC. 1 ENTERPRISE DRIVE, SUITE 430 SHELTON, CT 06484 July 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Intensity Therapeutics, Inc. Registration Statement on Form S-3 Filed July 3, 2024 File No. 333-280684 (the “Registration Statement”) Acceleration Request La
July 3, 2024	S-8	As filed with the Securities and Exchange Commission on July 3, 2024 As filed with the Securities and Exchange Commission on July 3, 2024 Registration No.
July 3, 2024	S-3	As filed with the Securities and Exchange Commission on July 3, 2024 ` As filed with the Securities and Exchange Commission on July 3, 2024 Registration No.
July 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Intensity Therapeutics, Inc.
July 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Intensity Therapeutics, Inc.
July 3, 2024	EX-4.3	Form of Senior Indenture Exhibit 4.3 INTENSITY THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities 1 CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313
July 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Intensity Therapeutics, Inc.
July 3, 2024	EX-4.4	Form of Subordinated Indenture Exhibit 4.4 INTENSITY THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a
July 3, 2024	S-3	As filed with the Securities and Exchange Commission on July 3, 2024 As filed with the Securities and Exchange Commission on July 3, 2024 Registration No.
July 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 Intensity Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commissi
July 3, 2024	EX-1.3	At The Market Offering Agreement, dated July 3, 2024, by and between Intensity Therapeutics, Inc. and H.C. Wainwright & Co., LLC. (incorporated by reference to Exhibit 1.3 of the Company’s Registration Statement on Form S-3 filed on July 3, 2024). Exhibit 1.3 AT THE MARKET OFFERING AGREEMENT July 3, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Intensity Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in
June 7, 2024	SC 13G	INTS / Intensity Therapeutics, Inc. / LFP Management, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INTENSITY THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45828J103 (CUSIP Number) 5/31/2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
June 4, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
June 4, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
May 24, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commissi
May 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Intensity Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commissi
May 15, 2024	EX-99.1	Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors Exhibit 99.1 Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors Shelton, CT, May 15, 2024 – Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
May 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Intensity Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commissio
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
May 9, 2024	EX-99.1	Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update •INT230-6, Intensity’s lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer •Cash and investments of $10.5 million expected to fund operations through the end of the first quarter of 2025 Shelton, CT, May 9, 2024 – Intensity Therapeutics
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commissio
April 19, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
March 14, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41109 INTENSITY THERAPEUTICS, INC.
March 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commis
March 14, 2024	EX-99.1	Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update •INT230-6, Intensity’s lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancer •Year-end cash and investments of $14.8 million expected to fund operations through the end of Q1 ’25 •Focusing on clinical operational and regulatory progress for a new technol
March 14, 2024	EX-97.1	Clawback Policy Exhibit 97.1 Intensity Therapeutics, inc. (the “Company”) Compensation Clawback Policy Effective Date: October 1, 2023 1. Purpose. The Company has adopted this Policy to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D of the Exchange Act, and Nasdaq Listing Rule 5608, which require the recovery of certain forms of executi
February 13, 2024	SC 13G	INTS / Intensity Therapeutics, Inc. / BENDER LEWIS H - SCHEDULE 13G Passive Investment SC 13G 1 ea193586-13gbenderintensity.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. )* INTENSITY THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class
February 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 Intensity Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Comm
February 7, 2024	EX-10.1	Incentive Compensation Plan Exhibit 10.1 Incentive Compensation Plan Adopted: February 6, 2024 Intensity Therapeutics offers an Incentive Compensation Plan (ICP), the “Plan,” to provide exempt salaried employees an opportunity to earn monetary awards based on Company Milestone Achievements and Individual Performance Objectives. PLAN OBJECTIVE The Plan incentivizes participants to achieve Individual Performance Objectives/Key
December 12, 2023	EX-10.1	Employment Agreement, dated December 11, 2023 between Registrant and Joseph Talamo Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of December 11, 2023, (the “Effective Date”), by and between INTENSITY THERAPEUTICS, Inc., a Delaware corporation (“INTENSITY” or “Company”), and Joseph Talamo (the “Employee”) with an address of 123 Harbor Drive, Unit 409; Stamford, CT 06902. 1. Employment. INTENSITY hereby employs the Employee to serve as Chief Fi
December 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 Intensity Thera UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Com
December 12, 2023	EX-99.1	Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held, development and commercial stage biopharmace Exhibit 99.1 Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held, development and commercial stage biopharmaceutical companies SHELTON, CT, December 12, 2023 – Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company foc
November 22, 2023	EX-3.1	Second Amended and Restated Bylaws, dated November 21, 2023 (incorporated by reference to Exhibit 3.1 of our Form 8-K filed on November 22, 2023). Exhibit 3.1 Second Amended and Restated Bylaws of Intensity Therapeutics, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 1 2.5 Notice of Nominations for Elec
November 22, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Com
November 13, 2023	EX-99.1	Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update Presented positive Phase 1/2 clinical data for INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue Oncology Society (“CTOS”), demon Exhibit 99.1 Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update Presented positive Phase 1/2 clinical data for INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue Oncology Society (“CTOS”), demonstrating 93% disease control rate in patients on monotherapy and survival extension of nearly 15 months vs. synthetic control group Recei
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Intensity Thera UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Com
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41109 Intensity Therapeutics, Inc.
September 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Intensity Thera UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Com
September 5, 2023	EX-99.1	Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference Exhibit 99.1 Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference WESTPORT, Conn., September 5, 2023 – Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition
September 5, 2023	EX-99.2	A New Weapon in the War on Cancer September 2023 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 Highlights • Novel cancer treatment approach with first - in - class compound that causes cancer cell death le Exhibit 99.2 A New Weapon in the War on Cancer September 2023 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 Highlights • Novel cancer treatment approach with first - in - class compound that causes cancer cell death leading to an immune response for indications with high unmet medical need • Late - stage pipeline programs in metastatic and presurgical s
August 22, 2023	EX-99.3	Form of Stock Option Award Agreement under the 2021 Stock Incentive Plan Exhibit 99.3 INTENSITY THERAPEUTICS, INC. STOCK OPTION AGREEMENT UNDER THE 2021 STOCK AND OPTION PLAN Signature Page Intensity Therapeutics, Inc. (the “Company”) hereby grants to you (the “Optionee”) the following option (“Option”) to purchase Common Stock of the Company: Name of Optionee: Total Number of Shares Subject to this Option: shares of Common Stock Type of Option: Exercise Price per Shar
August 22, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) Intensity Therapeutics, Inc.
August 22, 2023	EX-99.2	2021 Stock Incentive Plan Exhibit 99.2 Intensity Therapeutics Inc. 2021 STOCK INCENTIVE PLAN (dated as of November 12, 2021) Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this Intensity Therapeutics Inc. 2021 Stock Incentive Plan (as amended, this “Plan”) is to afford an incentive to Service Pr
August 22, 2023	S-8	As filed with the Securities and Exchange Commission on August 22, 2023 As filed with the Securities and Exchange Commission on August 22, 2023 Registration No.
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41109 Intensity Therapeutics, Inc.
August 14, 2023	EX-99.1	Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update Closed Upsized IPO Priced at Top-Of-Range, Full Exercise of the Over-Allotment Nets $20.4 Million in Proceeds Data Presented at ASCO Showed that Lead Asset Exhibit 99.1 Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update Closed Upsized IPO Priced at Top-Of-Range, Full Exercise of the Over-Allotment Nets $20.4 Million in Proceeds Data Presented at ASCO Showed that Lead Asset INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas Compa
August 14, 2023	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commi
August 14, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No.
July 10, 2023	EX-99.1	Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds Exhibit 99.1 Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds WESTPORT, Conn. July 10, 2023, – Intensity Therapeutics, Inc. (“Intensity” or the “Company”) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of pr
July 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Intensity Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commiss
July 5, 2023	EX-10.1	Underwriting Agreement, dated June 29, 2023 Exhibit 10.1 UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and The Benchmark Company, LLC as Representative of the Several Underwriters Intensity Therapeutics, Inc. UNDERWRITING AGREEMENT New York, New York June 29, 2023 The Benchmark Company, LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 150 East 58th St, 17th Floor New York, NY 10155 Ladies a
July 5, 2023	EX-4.1	Representative’s Warrant Exhibit 4.1 Form of Underwriter Warrant Intensity Therapeutics, Inc. Warrant Shares: Initial Exercise Date: January 5, 2023 Issue Date: July 5, 2023 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti
July 5, 2023	EX-99.1	Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds Exhibit 99.1 Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds WESTPORT, Conn. June 29, 2023, – Intensity Therapeutics, Inc. (“Intensity” or the “Company”) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therap
July 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Intensity Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Intensity Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41109 46-1488089 (State or Other Jurisdiction of Incorporation) (Commiss
July 5, 2023	EX-3.2	Amended and Restated Bylaws, dated July 5, 2023 Exhibit 3.2 Amended and Restated Bylaws of Intensity Therapeutics, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 2 2.5 Notice of Nominations for Election to
July 5, 2023	EX-3.1	Sixth Amended and Restated Certificate of Incorporation of the Registrant, dated June 30, 2023 (incorporated by reference to Exhibit 3.1 of our Form 8-K filed on July 5, 2023). Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTENSITY THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Intensity Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CER
July 5, 2023	EX-99.2	Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds Exhibit 99.2 Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds WESTPORT, Conn. July 5, 2023, – Intensity Therapeutics, Inc. (“Intensity” or the “Company”) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapi
June 30, 2023	424B4	3,900,000 Shares of Common Stock Filed pursuant to Rule 424(b)(4) Registration No. 333-260565 PROSPECTUS 3,900,000 Shares of Common Stock This is our initial public offering. We are offering 3,900,000 shares of our common stock, par value $0.0001 per share (“Common Stock”). Prior to this offering, there has been no public market for our Common Stock. The initial public offering price for our Common Stock is $5.00 per share. We ha
June 29, 2023	EX-FILING FEES	Filing Fee table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Intensity Therapeutics, Inc.
June 29, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Intensity Therapeutics, Inc.
June 29, 2023	S-1MEF	As filed with the Securities and Exchange Commission on June 29, 2023. As filed with the Securities and Exchange Commission on June 29, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of incorporation or organization
June 29, 2023	S-1/A	As filed with the Securities and Exchange Commission on June 29, 2023. As filed with the Securities and Exchange Commission on June 29, 2023. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 16 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of inc
June 27, 2023	CORRESP	June 27, 2023 June 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-260565 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representative o
June 27, 2023	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 June 27, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Intensity Therapeutics, Inc. (the “Regist
June 23, 2023	EX-10.15	Employment Agreement, dated June 20, 2023, between Registrant and John Wesolowski Exhibit 10.15 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of June 20, 2023 (the “Effective Date”), by and between INTENSITY THERAPEUTICS, Inc., a Delaware corporation (“INTENSITY” or “Company”), and John Wesolowski (the “Employee”). 1. Employment. INTENSITY hereby employs the Employee to serve as Controller, Principal Accounting Officer and interim Chief Financial Officer
June 23, 2023	S-1/A	Power of Attorney (included on signature page) As filed with the Securities and Exchange Commission on June 23, 2023. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 15 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of inc
June 23, 2023	FWP	A New Weapon in the War on Cancer June 2023 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 Safe Harbor and Forward - Looking Statements 2 Intensity Therapeutics, Inc . (the “Company” or “we”) has filed a re A New Weapon in the War on Cancer June 2023 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 Safe Harbor and Forward - Looking Statements 2 Intensity Therapeutics, Inc .
June 9, 2023	EX-10.11	Westport Lease Agreement Exhibit 10.11 OFFICE LEASE by and between Waldman Associates Limited Partnership (Landlord) and Intensity Therapeutics, Inc. (Tenant) Dated: January 16, 2017 TABLE OF CONTENTS 1. PREMISES. 1 2. ORIGINAL TERM. 1 3. RENEWAL TERM. 2 4. RENT. 2 5. CONSTRUCTION. 3 6. USE. 3 7. SERVICES. 3 8. UTILITIES. 3 9. INTERRUPTION OF SERVICES AND UTILITIES. 4 10. HVAC SERVICES. 4 11. REPAIRS. 4 12. YIELD UP AND F
June 9, 2023	EX-10.12	First Amendment to Westport Lease Agreement Exhibit 10.12 FIRST AMENDMENT OF LEASE THIS FIRST AMENDMENT OF LEASE (this “First Amendment”) made as of the day of November 2018, by and between WALP 57-61, LLC with a principal place of business c/o David Adam Realty, Inc., 57 Wilton Road, Westport, Connecticut 06880 (“Landlord”), and Intensity Therapeutics, Inc., with a place of business located at 61 Wilton Road, Westport, Connecticut, 06880 (
June 9, 2023	EX-10.14	Westport Lease Modification/Termination Agreement Exhibit 10.14 LEASE MODIFICATION/TERMINATION AGREEMENT THIS LEASE MODIFICATION/TERMINATION AGREEMENT made as of the 27 day of March, 2023, by and between WALP 57-61, LLC with a principal place of business c/o David Adam Realty, Inc., 57 Wilton Road, Westport, Connecticut 06880 (“Landlord”), and Intensity Therapeutics, Inc. (“Tenant”). WHEREAS, Landlord and Tenant desire to terminate the Lease date
June 9, 2023	S-1/A	As filed with the Securities and Exchange Commission on June 9, 2023. As filed with the Securities and Exchange Commission on June 9, 2023. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 14 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of inco
June 9, 2023	EX-10.13	Second Amendment to Westport Lease Agreement Exhibit 10.13 SECOND AMENDMENT OF LEASE THIS SECOND AMENDMENT OF LEASE (this “Second Amendment”) made as of the 20th day of July 2020, by and between WALP 57-61, LLC with a principal place of business c/o David Adam Realty. Inc., 57 Wilton Road, Westport, Connecticut 06880 (“Landlord”), and Intensity Therapeutics, Inc., with a place of business located at 6l Wilton Road, Westport, Connecticut, 068
June 9, 2023	CORRESP	June 9, 2023 mwe.com June 9, 2023 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Christopher Edwards Sasha Parikh Al Pavot Re: Intensity Therapeutics, Inc. Amendment No. 13 to Registration Statement on Form S-1 Filed May 18, 2023 File No. 333-260565 Dear Ms. Park: On behalf of Intensity Therapeutics, Inc
June 1, 2023	FWP	Issuer Free Writing Prospectus Filed Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333-260565
May 18, 2023	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and The Benchmark Company, LLC as Representative of the Several Underwriters Intensity Therapeutics, Inc. UNDERWRITING AGREEMENT New York, New York [●], 2023 The Benchmark Company, LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 150 East 58th St, 17th Floor New York, NY 10155 Ladies and Ge
May 18, 2023	EX-3.2	Certificate of Amendment to Certificate of Incorporation of the Registrant, as currently in effect Exhibit 3.2 CERTIFICATE OF AMENDMENT TO FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTENSITY THERAPEUTICS, INC. Intensity Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. This Certificate of Amendment (the
May 18, 2023	EX-FILING FEES	Filing Fee table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Intensity Therapeutics, Inc.
May 18, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 18, 2023. As filed with the Securities and Exchange Commission on May 18, 2023. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 13 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of inco
February 14, 2023	CORRESP	February 14, 2023 February 14, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
February 14, 2023	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 February 14, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Intensity Therapeutics, Inc. (the “Re
February 13, 2023	FWP	Filed Pursuant to Rule 433 of the Securities Act of 1933 Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated February 13, 2023 Relating to Preliminary Prospectus dated January 27, 2023 Registration No.
February 9, 2023	FWP	Filed Pursuant to Rule 433 of the Securities Act of 1933 FWP 1 ea173042-fwpintensity.htm FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated February 9, 2023 Relating to Preliminary Prospectus dated January 27, 2023 Registration No. 333-260565 This free writing prospectus relates to the initial public offering (“IPO”) of shares of common stock of Intensity Therapeutics, Inc. (the “Company
February 9, 2023	CORRESP	February 9, 2023 February 9, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-260565 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representativ
February 9, 2023	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 February 9, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Intensity Therapeutics, Inc. (the “Reg
February 8, 2023	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 February 8, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Intensity Therapeutics, Inc. (the “Reg
February 8, 2023	CORRESP	February 8, 2023 February 8, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
February 6, 2023	CORRESP	February 6, 2023 February 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-260565 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representativ
February 6, 2023	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 February 6, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Intensity Therapeutics, Inc. (the “Reg
January 27, 2023	CORRESP	January 27, 2023 mwe.com January 27, 2023 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Christopher Edwards Sasha Parikh Al Pavot Re: Intensity Therapeutics, Inc. Amendment No. 11 to Registration Statement on Form S-1 Filed January 13, 2023 File No. 333-260565 Dear Ms. Park: On behalf of Intensity Therapeut
January 27, 2023	S-1/A	As filed with the Securities and Exchange Commission on January 27, 2023. As filed with the Securities and Exchange Commission on January 27, 2023. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 12 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of
January 13, 2023	FWP	October 2021 A NEW WEAPON IN THE WAR ON CANCER Products that directly kill tumors to activate a patient - specific immune response Treating all stages of cancer January 2023 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Numbe October 2021 A NEW WEAPON IN THE WAR ON CANCER Products that directly kill tumors to activate a patient - specific immune response Treating all stages of cancer January 2023 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 Our vision : To extend patient life while maintaining good quality Intensity Therapeutics, Inc.
January 13, 2023	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and The Benchmark Company, LLC as Representative of the Several Underwriters Intensity Therapeutics, Inc. UNDERWRITING AGREEMENT New York, New York [●], 2023 The Benchmark Company, LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 150 East 58th St, 17th Floor New York, NY 10155 Ladies and Ge
January 13, 2023	S-1/A	As filed with the Securities and Exchange Commission on January 13, 2023. As filed with the Securities and Exchange Commission on January 13, 2023. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 11 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of
January 13, 2023	EX-FILING FEES	Filing Fee table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Intensity Therapeutics, Inc.
November 9, 2022	CORRESP	November 9, 2022 November 9, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 9, 2022	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 November 9, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our letter, filed
November 3, 2022	CORRESP	November 3, 2022 November 3, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-260565 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representativ
November 3, 2022	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 November 3, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Intensity Therapeutics, Inc. (the “Reg
November 2, 2022	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and Roth Capital Partners, LLC as Representative of the Several Underwriters Intensity Therapeutics, Inc. UNDERWRITING AGREEMENT New York, New York November [●], 2022 Roth Capital Partners, LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 888 San Clemente Drive, Suite 400 Newport Beach, CA
November 2, 2022	S-1/A	As filed with the Securities and Exchange Commission on November 2, 2022. As filed with the Securities and Exchange Commission on November 2, 2022. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 10 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of
November 2, 2022	CORRESP	November 2, 2022 mwe.com November 2, 2022 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Suzanne Hayes Sasha Parikh Al Pavot Re: Intensity Therapeutics, Inc. Amendment No. 9 to Registration Statement on Form S-1 Filed October 3, 2022 File No. 333-260565 Dear Ms. Park: On behalf of Intensity Therapeutics, Inc
October 13, 2022	CORRESP	October 13, 2022 October 13, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-260565 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representativ
October 13, 2022	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 October 13, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Intensity Therapeutics, Inc. (the “Reg
October 13, 2022	CORRESP	October 13, 2022 October 13, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
October 13, 2022	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 October 13, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our letter, filed
October 11, 2022	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 068809 October 11, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Intensity Therapeutics, Inc. (CIK 0001567264) Registration Statement No. 333-260565 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Intensity Therapeutics, Inc. (the “Reg
October 11, 2022	CORRESP	October 11, 2022 October 11, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-260565 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representativ
October 3, 2022	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and Roth Capital Partners, LLC as Representative of the Several Underwriters Intensity Therapeutics, Inc. UNDERWRITING AGREEMENT New York, New York [●], 2022 Roth Capital Partners, LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 57 W 57th Street, 18th Floor New York, New York 10019 Ladies
October 3, 2022	S-1/A	As filed with the Securities and Exchange Commission on October 3, 2022. As filed with the Securities and Exchange Commission on October 3, 2022. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 9 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of in
October 3, 2022	EX-FILING FEES	Filing Fee table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Intensity Therapeutics, Inc.
October 3, 2022	CORRESP	2 mwe.com October 3, 2022 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Christopher Edwards Sasha Parikh Al Pavot Re: Intensity Therapeutics, Inc. Amendment No. 8 to Registration Statement on Form S-1 Filed September 20, 2022 File No. 333-260565 Dear Ms. Park: On behalf of Intensity Therapeut
September 20, 2022	EX-4.2	Form of Underwriter Warrant Exhibit 4.2 UNDERWRITER COMMON STOCK PURCHASE WARRANT Intensity Therapeutics, Inc. Warrant Shares: Initial Exercise Date: Issue Date: THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
September 20, 2022	EX-10.6	Consulting Services Agreement, dated August 20, 2022, between the Registrant and Rebecca Drain Exhibit 10.6
September 20, 2022	FWP	October 2021 A NEW WEAPON IN THE WAR ON CANCER Products that directly kill tumors to activate a patient - specific immune response Treating all stages of cancer September 2022 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Num October 2021 A NEW WEAPON IN THE WAR ON CANCER Products that directly kill tumors to activate a patient - specific immune response Treating all stages of cancer September 2022 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 Our vision : To extend patient life while maintaining good quality Intensity Therapeutics, Inc.
September 20, 2022	EX-1.1	Form of Underwriting Agreement EX-1.1 2 fs12022a8ex1-1intensity.htm FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and Roth Capital Partners, LLC as Representative of the Several Underwriters Intensity Therapeutics, Inc. UNDERWRITING AGREEMENT New York, New York [●], 2022 Roth Capital Partners, LLC As Representative of the several Underwriters named on Schedule 1 attached
September 20, 2022	S-1/A	As filed with the Securities and Exchange Commission on September 19, 2022. As filed with the Securities and Exchange Commission on September 19, 2022. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 8 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of
September 20, 2022	EX-FILING FEES	Filing Fee table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Intensity Therapeutics, Inc.
May 16, 2022	EX-4.4	Form of Unit Purchase Option Exhibit 4.4 [FORM OF UNDERWRITERS UNIT PURCHASE OPTION] THE REGISTERED HOLDER OF THIS UNIT PURCHASE OPTION BY ITS ACCEPTANCE HEREOF, AGREES THAT THE SECURITIES EVIDENCED BY THIS UNIT PURCHASE OPTION MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS UNIT PURCHASE OPTION AGREES THAT THE SECURITIES EVIDENCED BY THIS UNIT PURCHASE OPTION WILL NOT BE S
May 16, 2022	CORRESP	May 16, 2022 mwe.com May 16, 2022 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Christopher Edwards Sasha Parikh Al Pavot Re: Intensity Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed November 12, 2021 File No. 333-260565 Dear Ms. Park: On behalf of Intensity Therapeutics,
May 16, 2022	S-1/A	As filed with the Securities and Exchange Commission on May 16, 2022. As filed with the Securities and Exchange Commission on May 16, 2022. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 7 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of incor
April 20, 2022	EX-FILING FEES	Filing Fee table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Intensity Therapeutics, Inc.
April 20, 2022	FWP	October 2021 A NEW WEAPON IN THE WAR ON CANCER Directly killing tumors to activate a patient - specific immune response Treating all stages of cancer April 2022 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 26056 October 2021 A NEW WEAPON IN THE WAR ON CANCER Directly killing tumors to activate a patient - specific immune response Treating all stages of cancer April 2022 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 Novel, Highly Tumor Diffusive Cytotoxic Drug Products Dosed into Tumors Intensity Therapeutics, Inc.
April 20, 2022	EX-4.2	Form of Warrant (included in Exhibit 4.2) Exhibit 4.2 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (?Warrant Agreement?) is made as of [?], 2022, by and between Intensity Therapeutics, Inc., a Delaware corporation, with offices at 61 Wilton Road, 3rd Floor, Westport, CT 06880 (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (collectively, the ?Warrant Agent?). WHEREAS, the C
April 20, 2022	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and Roth Capital Partners, LLC as Representative of the Several Underwriters Intensity Therapeutics, Inc. UNDERWRITING AGREEMENT New York, New York [●], 2022 Roth Capital Partners, LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 57 W 57th Street, 18th Floor New York, New York 10019 Ladies
April 20, 2022	S-1/A	As filed with the Securities and Exchange Commission on April 19, 2022. As filed with the Securities and Exchange Commission on April 19, 2022. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of inc
January 7, 2022	S-1/A	As filed with the Securities and Exchange Commission on January 7, 2022. As filed with the Securities and Exchange Commission on January 7, 2022. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (State or other jurisdiction of in
January 7, 2022	FWP	FREE WRITING PROSPECTUS
December 16, 2021	FWP	October 2021 A NEW WEAPON IN THE WAR ON CANCER Directly killing tumors to activate a patient - specific immune response Treating all stages of cancer December 2021 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 26 FWP 1 ea152517-fwpintensitytherap.htm FREE WRITING PROSPECTUS October 2021 A NEW WEAPON IN THE WAR ON CANCER Directly killing tumors to activate a patient - specific immune response Treating all stages of cancer December 2021 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 2 2 SAFE HARBOR AND FORWARD - LOOKING STATEMENTS Intensity Therapeutics, Inc. (the
December 10, 2021	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 06880 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 06880 December 9, 2021 VIA EDGAR Division of Corporation Finance Office of Trade and Services U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-260565) Ladies and Gentlemen: Reference is made to our letter, filed as corres
December 10, 2021	CORRESP	[Signature Page Follows] December 9, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-260565) Ladies and Gentlemen: Reference is made to our letter, filed as corrvespondence via EDGAR on December 7, 2021, in which we, as representative of the underwriters of the offering,
December 9, 2021	S-1/A	As filed with the Securities and Exchange Commission on December 9, 2021. S-1/A 1 fs12021a4intensitythera.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on December 9, 2021. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter)
December 9, 2021	CORRESP	December 9, 2021 mwe.com December 9, 2021 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Christopher Edwards Sasha Parikh Al Pavot Re: Intensity Therapeutics, Inc. Amendment No. 3 to Registration Statement on Form S-1 Filed December 8, 2021 File No. 333-260565 Dear Ms. Park: On behalf of Intensity Therapeuti
December 8, 2021	EX-3.2	Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect immediately prior to the completion of the offering Exhibit 3.2 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTENSITY THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Intensity Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CER
December 8, 2021	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and A.G.P./Alliance Global Partners as Representative of the Several Underwriters Intensity Therapeutics, Inc. UNDERWRITING AGREEMENT New York, New York [●], 2020 A.G.P./Alliance Global Partners As Representative of the several Underwriters named on Schedule 1 attached hereto 590 Madison Avenue, 28th Floor New York, New York 1
December 8, 2021	EX-10.3	2021 Equity Incentive Plan EX-10.3 8 fs12021a3ex10-3intensity.htm 2021 EQUITY INCENTIVE PLAN Exhibit 10.3 Intensity Therapeutics Inc. 2021 STOCK INCENTIVE PLAN (dated as of , 2021) Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this Intensity Therapeutics Inc. 2021 Stock Incentive Plan (as amende
December 8, 2021	EX-4.1	Specimen Common Stock Certificate evidencing the shares of Common Stock Exhibit 4.1 Intensity Therapeutics, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK THIS IS TO CERTIFY that NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 45828J 103 is the owner of Fully paid non-assessable Shares of Common Stock of Intensity Therapeutics, Inc. (the “Corporation”) transferable on the books of the Corporation in person or by duly authorized attor
December 8, 2021	EX-3.4	Form of Amended and Restated By-Laws of the Registrant, to be in effect immediately prior to the completion of the offering Exhibit 3.4 Amended and Restated Bylaws of Intensity Therapeutics, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 1 2.5 Notice of Nominations for Election to
December 8, 2021	EX-10.4	Amended and Restated Employment Agreement between the Registrant and Lewis H. Bender Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into effective as of November 24, 2021 (the “Effective Date”) by and between Intensity Therapeutics, Inc., a Delaware corporation with a place of business at 61 Wilton Road, Westport Connecticut 06880 (the “Company” or “Intensity”) and Lewis H. Bender, residing at 43 Ledgewood Road, Redding CT 06896
December 8, 2021	EX-10.1	Form of Indemnification Agreement by and between the Registrant and each of its directors and executive officers. Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Intensity Therapeutics, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnifica
December 8, 2021	S-1/A	As filed with the Securities and Exchange Commission on December 8, 2021. S-1/A 1 fs12021a3intensitythera.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on December 8, 2021. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter)
December 7, 2021	CORRESP	[Signature Page Follows] EXECUTION VERSION December 7, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-260565) Acceleration Request Requested Date: December 9, 2021 Requested Time: 5:00 p.m. Eastern Standard Time Ladies and Gentlemen: In accordance with Rule 461 under the
December 7, 2021	CORRESP	Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 06880 Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 06880 December 7, 2021 VIA EDGAR Division of Corporation Finance Office of Trade and Services U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 RE: Intensity Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-260565) (the “Registration Statement”) Ladies and Gentlemen: T
December 2, 2021	8-A12B/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A Amendment No. 1 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Intensity Therapeutics, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A Amendment No.
November 30, 2021	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Intensity Therapeutics, Inc. (Exact Name of Reg UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Intensity Therapeutics, Inc.
November 24, 2021	FWP	October 2021 A NEW WEAPON IN THE WAR ON CANCER Directly killing tumors to activate a patient - specific immune response Treating all stages of cancer November 2021 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 26 October 2021 A NEW WEAPON IN THE WAR ON CANCER Directly killing tumors to activate a patient - specific immune response Treating all stages of cancer November 2021 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260565 2 2 SAFE HARBOR AND FORWARD - LOOKING STATEMENTS Intensity Therapeutics, Inc.
November 18, 2021	CORRESP	2 mwe.com November 18, 2021 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Christopher Edwards Sasha Parikh Al Pavot Re: Intensity Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed November 12, 2021 File No. 333-260565 Dear Ms. Park: On behalf of Intensity Therapeu
November 18, 2021	S-1/A	As filed with the Securities and Exchange Commission on November 18, 2021. S-1/A 1 fs12021a2intensitytherap.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on November 18, 2021. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charte
November 12, 2021	EX-10.9	Material Transfer and Collaboration Agreement, dated March 18, 2021, between the Registrant and Ontario Institute for Cancer Research, Ottawa Hospital Research Institute and Dr. Angel Arnaout Exhibit 10.9 [CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.] MATERIAL TRANSFER AND COLLABORATION AGREEMENT THIS AGREEMENT is entered into and made effective as of the date of last signature (the “Effective Date”), BETWEE
November 12, 2021	EX-10.2	2013 Stock and Option Plan, as amended Exhibit 10.2 INTENSITY THERAPEUTICS, INC. 2013 STOCK AND OPTION PLAN SECTION 1 TITLE This Plan shall be known as the Intensity Therapeutics, Inc. 2013 Stock and Option Plan. SECTION 2 PURPOSE The purpose of the Plan is to advance the interests of the Company by providing key employees and certain other persons with opportunities to participate in the ownership of the Company and its future growth
November 12, 2021	CORRESP	2 mwe.com November 12, 2021 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Christopher Edwards Sasha Parikh Al Pavot Re: Intensity Therapeutics, Inc. Registration Statement on Form S-1 Filed October 28, 2021 File No. 333-260565 Dear Ms. Park: On behalf of Intensity Therapeutics, Inc., a Delawa
November 12, 2021	S-1/A	As filed with the Securities and Exchange Commission on November 12, 2021. S-1/A 1 fs12021a1intensitytherap.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on November 12, 2021. Registration No. 333-260565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charte
October 28, 2021	S-1	Power of Attorney (included on signature page) S-1 1 fs12021intensitytherap.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on October 28, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intensity Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1488089 (S
October 28, 2021	EX-10.8	Clinical Trial Collaboration and Supply Agreement, dated June 21, 2019, between the Registrant and MSD International GmbH Exhibit 10.8 [CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.] CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and between MSD International GmbH, and Intensity Therapeutics, Inc. Dated: June 21, 2019 TABLE OF CONTENT
October 28, 2021	EX-10.7	Clinical Trial Collaboration and Supply Agreement, dated April 13, 2020, between the Registrant and Bristol-Myers Squibb Company Exhibit 10.7 [CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.] CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This Clinical Trial Collaboration and Supply Agreement (the ?Agreement?) is made and entered into effective a
October 28, 2021	EX-10.6	Employment Agreement, dated August 25, 2014, between the Registrant and Ian B. Walters Exhibit 10.6 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of August 25, 2014 (the “Effective Date”), by and between INTENSITY THERAPEUTICS, Inc., a Delaware corporation (“INTENSITY” or “Company”), and Ian B. Walters (the “Employee”). 1. Employment. INTENSITY hereby employs the Employee to serve as Vice President and Chief Medical Officer of INTENSITY in accordance with the
October 28, 2021	CORRESP	2 mwe.com October 28, 2021 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sasha Parikh Al Pavot Jane Park Christopher Edwards Re: Intensity Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted September 20, 2021 CIK No. 0001567264 Dear Ms. Parikh: On behalf of Intensity Therapeutics, In
October 28, 2021	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Intensity Therapeutics, Inc. Legal Name Jurisdiction None -
October 28, 2021	EX-10.5	Employment Agreement, dated June 21, 2019, between the Registrant and Rebecca “Peggi” Drain Exhibit 10.5 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of June 21, 2019, (the “Effective Date”), by and between INTENSITY THERAPEUTICS, Inc., a Delaware corporation (“INTENSITY” or “Company”), and Rebecca “Peggi” Drain (the “Employee”) with an address of 86 River Road, Killingworth, CT 06419. 1. Employment. INTENSITY hereby employs the Employee to serve as Executive Dir
October 28, 2021	EX-3.3	By-Laws of the Registrant, as currently in effect Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF INTENSITY THERAPEUTICS, INC. ARTICLE I CORPORATE OFFICES SECTION 1. Registered Office. Pursuant to these bylaws, as may be amended or amended and restated from time to time (the “Bylaws”), the president of Intensity Therapeutics, Inc. (the “Corporation”) shall from time to time designate the registered office and the registered agent of the Corporation. S
October 28, 2021	EX-3.1	Certificate of Incorporation of the Registrant, as currently in effect Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTENSITY THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Intensity Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CER
September 20, 2021	DRS	As confidentially submitted to the Securities and Exchange Commission on September 20, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confide As confidentially submitted to the Securities and Exchange Commission on September 20, 2021.

INTS / Intensity Therapeutics, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)